<DOC>
	<DOCNO>NCT02782897</DOCNO>
	<brief_summary>This pilot study aim investigate whether intravenous immunoglobulin safe effective alleviate perihematomal edema neurologic deficit patient intracranial hemorrhage .</brief_summary>
	<brief_title>Intravenous Immunoglobulin Acute Intracranial Hemorrhage</brief_title>
	<detailed_description>The trial consist two group : IVIg group control group . Thirty patient recruited IVIg group . Thirty Patients matched age , gender , National Institutes Health Stroke Scale score , hematomal volume , location hematomas , select control group . Patients control group receive standard management , IVIg group receive standard management plus intravenous immunoglobulin therapy . The outcome assessor blind group assignment .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Intracranial Hemorrhage , Hypertensive</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . The firstever primary supratentorial intracerebral basal ganglia hemorrhage 530ml . 2 . 1880 year old . 3 . No longer 72 hour acute ICH medication . 4 . Glasgow Coma Score ≥8 . 1 . Occurrences secondary intracerebral hemorrhage . 2 . Significant past history disability , modify Rankin Scale（mRS）≥1 . 3 . Currently take antitumor drug , immunosuppressive drug , immunomodulatory therapy . 4 . Patients pregnancy , Severe infection , severe heart dysfunction renal hepatic injury . 5 . Patients contraindication immunoglobulin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>intravenous immunoglobulin</keyword>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>perihematomal edema</keyword>
</DOC>